S&P Futures
4,131.00-1.75(-0.04%)Dow Futures
33,527.00-43.00(-0.13%)Nasdaq Futures
13,966.50-9.25(-0.07%)
ANI Pharmaceuticals, Inc. (ANIP)
33.03 0.00 (0.00%)
After hours: 4:01PM EDT
Chart Events
Performance Outlook
| Previous Close | 32.39 |
| Open | 32.17 |
| Bid | 29.00 x 800 |
| Ask | 33.91 x 1000 |
| Day's Range | 31.69 - 33.25 |
| 52 Week Range | 23.55 - 52.22 |
| Volume | 49,817 |
| Avg. Volume | 56,650 |
| Market Cap | 408.426M |
| Beta (5Y Monthly) | 1.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.88 |
| Earnings Date | Mar 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs
ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ:ANIP) today announced that it has acquired the new drug applications ("NDAs") for OXISTAT® Lotion, VEREGEN® Ointment, and Pandel® Cream and the abbreviated new drug application ("ANDA") for ApexiCon® E Cream from Sandoz Inc. Pandel® Cream will be transitioned later upon receiving the requisite approvals. Collectively, these products generated net revenues of $13.2 million in 2020. The acquisition was funded through borrowings under the Company’s pre-existing revolver credit facility.
- Zacks
ANI Pharmaceuticals (ANIP) Enters Overbought Territory
ANI Pharmaceuticals (ANIP) has moved higher as of late, but there could definitely be trouble on the horizon for this company
- Motley Fool
ANI Pharmaceuticals Inc (ANIP) Q4 2020 Earnings Call Transcript
It's now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for ANI Pharmaceuticals. This is Lisa Wilson of In-Site Communications, Investor Relations for ANI. With me on today's call are Nikhil Lalwani, President and Chief Executive Officer and Steve Carey, Chief Financial Officer of ANI.
